The World Health Organization (WHO) has raised urgent concerns regarding three hazardous cough syrups after a tragic incident in Madhya Pradesh, India, where numerous children fell critically ill. This report aims to provide an overview of the situation, the specific products involved, and the ongoing responses by Indian authorities.
Key Updates from the WHO
On October 14, 2025, the WHO released a health alert regarding the following contaminated products:
- Coldrif from Sresan Pharmaceutical
- Respifresh TR from Rednex Pharmaceuticals
- ReLife from Shape Pharma
Authorities are urged globally to report any findings of these syrups as they are deemed extremely dangerous, posing severe and potentially fatal health risks.
Background of the Tragedy
In a deeply concerning development, the Central Drugs Standard Control Organisation (CDSCO) of India reported that children under the age of five in Chhindwara district, Madhya Pradesh, ingested the contaminated syrups. Tragically, at least 22 children, primarily from the town of Parasia, have died, with more hospitalized in Nagpur, Maharashtra.
Chemical tests showed that these cough syrups contained diethylene glycol (DEG) at shocking levels—almost 500 times the safe limit. The CDSCO confirmed that none of the affected batches were exported from India, and there was no evidence of illegal shipments being made beyond the country’s borders. The U.S. Food and Drug Administration (FDA) stated these toxic products were not sent to the United States.
Response from Indian Authorities
In light of these alarming developments, multiple states across India have imposed bans on certain cough syrups. Some have gone as far as prohibiting all cough and cold medications for children under the age of two. The swift legislative responses are aimed at ensuring kid’s safety and preventing further tragedies.
In Tamil Nadu, authorities took decisive action by revoking the manufacturing license of Sresan Pharmaceutical, the company implicated in producing syrup with excessive levels of DEG. The Tamil Nadu government announced that the company’s production license has been fully canceled, and operations have been halted. Furthermore, they launched thorough inspections of other pharmaceutical manufacturing units within the state.
In connection with the case, the owner of Sresan Pharmaceuticals, G Ranganathan, was arrested by a specialized investigation team from Madhya Pradesh. Earlier that week, the Enforcement Directorate also conducted raids at the company’s facilities as a part of a larger investigation concerning violations of the Prevention of Money Laundering Act.
Conclusion: A Call for Caution
The recent events highlight the critical need for stringent regulatory measures in pharmaceutical production to prevent such tragedies from occurring in the future. Parents and caregivers are advised to exercise utmost caution when administering cough syrups, particularly to young children, and to be aware of the possible risks involved.
For ongoing updates, please stay informed through trusted health news sources and check official health alerts from the WHO and local health authorities. The health and safety of children should remain a top priority as investigations continue to ensure that no unsafe products are available on the market.
For further insights, check our health category at Axom Live Health
